Literature DB >> 21642594

Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154.

Nina Khanna1, Claudia Stuehler, Barbara Conrad, Sarah Lurati, Sven Krappmann, Hermann Einsele, Carsten Berges, Max S Topp.   

Abstract

Viral and fungal infections remain a leading cause of mortality in patients after hematopoietic stem cell transplantation (HSCT). Adoptive transfer of multipathogen-specific T cells is promising in restoring immunity and thereby preventing and treating infections, but approaches are currently limited because of time-consuming and laborious procedures. Therefore, we investigated a new strategy to simultaneously select T cells specific for viral and fungal pathogens based on activation-dependent expression of CD154. Single- and multipathogen-specific T-cell lines with high specificity for adenovirus (AdV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), Candida albicans, and/or Aspergillus fumigatus could be readily generated within 14 days irrespective of the precursor frequency. The T-cell lines responded reproducibly to endogenously processed antigen and specifically proliferated upon antigenic stimulation. Although isolation based on CD154 favors enrichment of CD4(+) T cells, AdV-, EBV- and CMV-specific CD8(+) T cells could be expanded and demonstrated lysis of target cells. Conversely, T cell-mediated alloreactivity was almost abrogated compared with the starting fraction. This selection and/or expansion strategy may form the basis for future adoptive immunotherapy trials in patients at risk for multiple infections and may be translated to other antigens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642594     DOI: 10.1182/blood-2010-12-322610

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

Review 2.  Emerging concepts in haematopoietic cell transplantation.

Authors:  Hao Wei Li; Megan Sykes
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 3.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 4.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 5.  Universal fungal vaccines: could there be light at the end of the tunnel?

Authors:  Mawieh Hamad
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

6.  Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.

Authors:  Anthony Garnier; Mohamad Hamieh; Aurélie Drouet; Jérôme Leprince; Denis Vivien; Thierry Frébourg; Brigitte Le Mauff; Jean-Baptiste Latouche; Olivier Toutirais
Journal:  Immunol Cell Biol       Date:  2016-02-29       Impact factor: 5.126

Review 7.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

Review 8.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

9.  Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.

Authors:  Hetty Jolink; Renate S Hagedoorn; Ellen L Lagendijk; Jan W Drijfhout; Jaap T van Dissel; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

10.  Targeting EBV's Achilles' heel with antigen-specific T cells.

Authors:  Mamta Kalra; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2013-04       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.